GE HealthCare (Nasdaq: GEHC) today unveiled CareIntellect for Oncology, a new, cloud-first application utilizing generative AI.
The application brings together multi-modal patient data from disparate systems into a single view. It leverages generative AI to summarize clinical notes and reports.
GE HealthCare designed the application to surface relevant data. This allows care teams to quickly understand disease progression and flag potential deviations from the treatment plan. That helps clinicians determine potential next steps and inform proactive interventions.
Chicago-based GE HealthCare plans to make its application available to U.S. customers next year, with an initial focus on prostate and breast cancer. It organizes structured and unstructured data, summarizes complex medical histories, supports treatment response assessments, helps assess clinical trial eligibility and tracks adherence to treatment protocols in an easy-to-navigate view.
GE HealthCare said this marks the first application within its new CareIntellect offering of clinical and operational applications. It designed these apps to help healthcare providers quickly and easily install new applications without having to take a costly and time-consuming product-by-product integration approach.
Tampa General Hospital and UT Southwestern Medical Center agreed to serve as early evaluators of CareIntellect for Oncology. GE HealthCare already has integration underway at those sites. It plans for wide availability to U.S. customers in 2025, with future expansion anticipated for Canada, the UK and Ireland.
“CareIntellect is designed to help providers streamline access to critical patient information and surface key changes since the patient’s last visit,” said Dr. Taha Kass-Hout, global chief science and technology officer at GE HealthCare. “By ensuring the provider has the right information at their fingertips, they can spend less time sifting through information and more time helping patients.”